GlassScriptPrepare for your visit
Ami B Bhatt
Cardiovascular Disease · Boston, MA · NPI 1285600155
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$36,868.52
in general payments reported to CMS, 2019-2025 · $1,160 in 2025
The $1,160 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Who reported paying
General payments only, top 6 by amount.
- Astrazeneca Pharmaceuticals LP $16,110.00
- E.R. Squibb & Sons, L.L.C. $14,350.00
- Novartis Pharmaceuticals Corporation $2,567.22
- Actelion Pharmaceuticals, LTD $1,770.00
- Ge Healthcare $1,160.00
- Edwards Lifesciences Corporation $343.04
Drugs and devices associated with these payments
Briefcase Dragonfly Opstar Cadscor System
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Ami Bhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/457598/ami-b-bhatt